Clinical trial NCT03714529: A Study of IO103 in Montanide Adjuvant for Basal Cell Carcinoma
Official title: Phase IIa Trial With PD-L1 IO103 Vaccination With Montanide in Patients With Basal Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Basal Cell Carcinoma
Lead sponsor: Herlev and Gentofte Hospital
Sponsor class: OTHER
Collaborators: name: University of Copenhagen
First posted: 2018-10-22
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A single center, open-label, phase IIa, single arm, window of opportunity trial with IO103 and Montanide adjuvant in patients with surgically resectable BCC.

Detailed description: 10 patients with BCC will be vaccinated with a peptide derived from the immune checkpoint molecule PD-L1. Patients will be vaccinated once every 2 weeks (Q2W) for 10 weeks and then evaluated for a clinical response.

Patients with clinical response to vaccination will continue with one vaccination once every 4 weeks (Q4W) for 12 weeks and thus receive 9 vaccinations in total over the course of 22 weeks.

Patients with no effect of treatment after 6 vaccinations will be treated with standard of care (SOC).

Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18
2. At least 1 histological verified superficial or nodular basal cell carcinoma on the body or limbs of bigger than 14 mm in the longest diameter
3. Willing to provide three 4 mm biopsies from the lesion/lesions
4. Not previously treated with a hedgehog pathway inhibitor
5. For women of childbearing potential: Agreement to use contraceptive methods with a failure rate of \< 1 % per year during the treatment period and for at least 150 days after the treatment. Safe contraceptive methods for women are birth control pills, intrauterine device, contraceptive injection, contraceptive implant, contraceptive patch or contraceptive vaginal ring.
6. For men: Agreement to use contraceptive measures and agreement to refrain from donating sperm
7. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial in accordance with ICH-GCP and local legislation prior to admission to the trial
8. Sufficient bone marrow function, i.e.

   1. Leucocytes ≥ 1,5 x 109
   2. Granulocytes ≥ 1,0 x 109
   3. Thrombocytes ≥ 20 x 109

2. Creatinine \< 2.5 upper normal limit, i.e. \< 300 μmol/l 3. Sufficient liver function, i.e.

1. ALAT \< 2.5 upper normal limit, i.e. ALAT \<112 U/l
2. Bilirubin \< 30 U/l

Exclusion Criteria:

1. The patient has a history of life-threatening or severe immune related adverse events on treatment with another immunotherapy and is considered to be at risk of not recovering
2. The patient has a history of severe clinical autoimmune disease
3. The patient has a history of pneumonitis, organ transplant, human immunodeficiency virus positive, active hepatitis B or hepatitis C
4. The patient has any condition that will interfere with patient compliance or safety (including but not limited to psychiatric or substance abuse disorders)
5. The patient is pregnant or breastfeeding
6. The patient has an active infection requiring systemic therapy
7. The patient has received a live virus vaccine within 30 days of planned start of therapy
8. Known side effects to Montanide ISA-51
9. Significant medical disorder according to investigator; e.g. severe asthma or chronic obstructive lung disease, dysregulated heart disease or dysregulated diabetes mellitus
10. Concurrent treatment with other experimental drugs
11. Any active autoimmune diseases e.g. autoimmune neutropenia, thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, scleroderma, myasthenia gravis, autoimmune glomerulonephritis, autoimmune adrenal deficiency, autoimmune thyroiditis etc.
12. Severe allergy or anaphylactic reactions earlier in life.

Primary outcomes:
measure: Clinical response
timeFrame: All patients were evaluated 3 Month after last vaccination
measure: Disease control rate
timeFrame: After 6 vaccinations with IO103 (10 weeks)
measure: Immune responses
timeFrame: After 6 vaccinations with IO103 (10 weeks)
Secondary outcomes:
measure: Immune responses in skin
timeFrame: After 6 vaccinations with IO103 (10 weeks)
measure: Incidence of treatment emergent adverse events (safety and tolerability)
timeFrame: From the time that the subject provides written informed consent and throughout the trial duration, until 30 days post last dose of trial treatment
Other outcomes:
Locations:
city: Hellerup
country: Denmark
facility: Herlev and Gentofte Hospital
state: Hovedstaden
Study officials:
affiliation: Herlev and Gentofte Hospital
name: Inge Marie Svane, Prof
role: STUDY_DIRECTOR
References:
citation: Munir Ahmad S, Martinenaite E, Hansen M, Junker N, Borch TH, Met O, Donia M, Svane IM, Andersen MH. PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. Oncoimmunology. 2016 Jul 1;5(8):e1202391. doi: 10.1080/2162402X.2016.1202391. eCollection 2016 Aug.